

Notification of attendance and form for advance voting

The form must be received by Hansa Biopharma AB (publ) no later than June 18, 2025.

The shareholder below is hereby notifying the company of its participation and exercising the voting right for all of the shareholder's shares in Hansa Biopharma AB (publ), Reg. No. 556734-5359, at the Annual General Meeting on June 25, 2025. The voting right is exercised in accordance with the voting options marked below.

Shareholder	Personal identity number/registration number

Assurance (if the undersigned is a legal representative of a shareholder who is a legal entity): I, the undersigned, am a board member, the CEO or a signatory of the shareholder and solemnly declare that I am authorised to submit this advance vote on behalf of the shareholder and that the contents of the advance vote correspond to the shareholder's decisions.

Assurance (if the undersigned represents the shareholder by proxy): The undersigned solemnly declare that the enclosed power of attorney corresponds to the original and has not been revoked.

Place and date	
Signature	
Clarification of signature	
Telephone number	E-mail

Instructions

- Complete all the requested information above
- Select the preferred voting options below
- Print, sign and send the form in original to Advokatfirman Vinge KB, Att: Annie Fällström, Box 1703, SE-111 87 Stockholm, Sweden. A completed and signed form may also be submitted electronically and shall, in that case, be sent to hansabiopharma@vinge.se
- If the shareholder is a natural person who is personally voting in advance, it is the shareholder who should sign under *Signature* above. If the advance vote is submitted by a proxy of the shareholder, it is the proxy who should sign. If the advance vote is submitted by a legal representative of a legal entity, it is the representative who should sign
- If the shareholder votes by proxy, a proxy shall be enclosed to the form. If the shareholder is a legal entity, a certificate of incorporation or an equivalent certificate of authority should be enclosed to the form

A shareholder whose shares have been registered in the name of a bank or securities institute must register its shares in its own name to vote. Instructions for this is included in the notice convening the General Meeting.

A shareholder cannot give any other instructions than selecting one of the options specified at each point in the form. If a shareholder wishes to abstain from voting in relation to a matter, kindly refrain from selecting an option. A vote (*i.e.* the advance vote in its entirety) is invalid if the shareholder has provided the form with specific instructions or conditions or if pre-printed text is amended or supplemented.

The advance voting form, together with any enclosed authorisation documentation, shall be provided to Hansa Biopharma no later than June 18, 2025. An advance vote can be withdrawn up to and including June 18, 2025 by contacting hansabiopharma@vinge.se.

One form per shareholder will be considered. If more than one form is submitted, the form with the latest date will be considered. The form latest received by Hansa Biopharma will be considered if two forms are dated at the same date. An incomplete or wrongfully completed form may be discarded without being considered. If a shareholder has voted in advance and attends the Annual General Meeting in person or through a proxy, the advance vote is still valid except to the extent the shareholder participates in a voting procedure at the General Meeting or otherwise withdraws its casted advance vote. If the shareholder chooses to participate in a voting at the General Meeting, the vote cast will replace the advance vote with regard to the relevant item on the agenda.

Note that the advance vote does not constitute a notification to participate in the General Meeting at the venue in person or through proxy. Instructions for shareholders who wish to participate in the Annual General Meeting at the venue in person or represented by a proxy are included in the notice convening the Meeting.

For the complete proposals, kindly refer to the notice convening the General Meeting and the company's website www.hansabiopharma.com.

For information on how your personal data is processed, see the integrity policy that is available at Euroclear's website, www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.

Annual General Meeting in Hansa Biopharma AB (publ) on June 25, 2025

The options below comprise the submitted proposals included in the notice convening the Annual General Meeting and are held available on the company's website.

2. Election of chair of the meeting Yes <input type="checkbox"/> No <input type="checkbox"/>
4. Approval of the agenda Yes <input type="checkbox"/> No <input type="checkbox"/>
6. Determination as to whether the meeting has been duly convened Yes <input type="checkbox"/> No <input type="checkbox"/>
8(a) Resolution regarding the adoption of the income statement and the balance sheet, and of the consolidated income statement and the consolidated balance sheet Yes <input type="checkbox"/> No <input type="checkbox"/>
8(b) Resolution regarding allocation of the company's result according to the adopted balance sheet Yes <input type="checkbox"/> No <input type="checkbox"/>
8(c) Resolution regarding discharge from liability for the members of the Board of Directors and the CEO
8(c)(i) Peter Nicklin, chair of the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>
8(c)(ii) Anders Gersel Pedersen, member of the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>
8(c)(iii) Eva Nilsagård, member of the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>
8(c)(iv) Hilary Malone, member of the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>
8(c)(v) Mats Blom, member of the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>
8(c)(vi) Jonas Wikström, member of the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>
8(c)(vii) Florian Reinaud, member of the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>
8(c)(viii) Andreas Eggert, former member of the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>
8(c)(ix) Søren Tulstrup, former CEO Yes <input type="checkbox"/> No <input type="checkbox"/>
9(a) Determination of the number of members of the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>
9(b) Determination of the number of auditors

Yes <input type="checkbox"/> No <input type="checkbox"/>
10(a) Determination of fees for members of the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>
10(b) Determination of fees for auditors Yes <input type="checkbox"/> No <input type="checkbox"/>
11. Election of the members of the Board of Directors
11(a) Mats Blom (re-election) Yes <input type="checkbox"/> No <input type="checkbox"/>
11(b) Anders Gersel Pedersen (re-election) Yes <input type="checkbox"/> No <input type="checkbox"/>
11(c) Hilary Malone (re-election) Yes <input type="checkbox"/> No <input type="checkbox"/>
11(d) Peter Nicklin (re-election) Yes <input type="checkbox"/> No <input type="checkbox"/>
11(e) Eva Nilsagård (re-election) Yes <input type="checkbox"/> No <input type="checkbox"/>
11(f) Florian Reinaud (re-election) Yes <input type="checkbox"/> No <input type="checkbox"/>
11(g) Jonas Wikström (re-election) Yes <input type="checkbox"/> No <input type="checkbox"/>
12. Election of the chair of the Board of Directors Peter Nicklin (re-election) Yes <input type="checkbox"/> No <input type="checkbox"/>
13. Election of auditors KPMG AB (re-election) Yes <input type="checkbox"/> No <input type="checkbox"/>
14. Proposal regarding principles for appointing the Nomination Committee Yes <input type="checkbox"/> No <input type="checkbox"/>
15. Presentation of the Board of Directors' remuneration report for approval Yes <input type="checkbox"/> No <input type="checkbox"/>
16. Proposal for a long-term incentive program 2025
16(a) Proposal regarding the adoption of the Option and Warrant Program 2025 Yes <input type="checkbox"/> No <input type="checkbox"/>
16(b) Proposal regarding issue and transfer of warrants to secure delivery of shares pursuant to the terms of the employee stock options Yes <input type="checkbox"/> No <input type="checkbox"/>
16(c) Proposal regarding issue and transfer of warrants to participants at a price corresponding to the market value

Yes No

17. Proposal for resolution regarding transfer of own ordinary shares

Yes No

18. Proposal regarding resolution on authorization for the Board of Directors to resolve on new issue of ordinary shares and warrants and/or convertibles

18(a) Main proposal

Yes No

18(b) Alternative proposal

Yes No